Dear @hitesh2710 ji
I would like to hear your views about the recent announcement of Glenmark Pharma selling 75% of it’s stake in Glenmark Life Sciences to Nirma, which is a relatively new entrant in the pharma space.
Nirmal will get 75% plus shares that will be tendered in the mandatory open offer process. There is an old history with Nirma not treating the minority shareholders well. Times have changed now. Any advice for shareholders of GLS that want to hold their shares as the GLS business is quite good?
| Subscribe To Our Free Newsletter |
